82 results about "Ejection fraction" patented technology

A method of real time ultrasound imaging of an object in at least three two-dimensional scan planes that are rotated around a common axis, is given, together with designs of ultrasound transducer arrays that allows for such imaging. The method is also introduced into a monitoring situation of cardiac function where, combined with other measurements as for example the LV pressure, physiological parameters like ejection fraction and muscular fiber stress is calculated.

A method and system of cardiac contractility analysis is provided. Cardiac contractility may include indices such as ejection fraction (EF) and rate of change in pressure (dP / dt) in a heart. Heart sounds may be measured and calibrated by attenuation. Likewise, a first acoustic peak in the first heart sound (S1), and a second acoustic peak of the second heart sound (S2) may be identified. The first heart sound (S1) may be calibrated by the second heart sound (S2). Amplitudes of calibrated heart sounds may be correlated to cardiac contractility. Electrical activity and acoustics of the heart are measured. The pre-ejection period of the cardiac cycle may be calculated. The left ventricular ejection time of the cardiac cycle may likewise be calculated. Then a ratio of pre-ejection period over left ventricular ejection time may be calculated and correlated to cardiac contractility. Pressure on the acoustic sensor may be used to calibrate acoustic data.

A method for assessing cardiac function using an ultrasound imaging catheter system includes positioning an ultrasound catheter so the ultrasound transducer can image a ventricle, obtaining images of the ventricle at two or more times within the cardiac cycle, recognizing an edge of the endocardium, measuring dimensions of the ventricle, calculating a volume or area of the ventricle at the two or more points in the cardiac cycle, and calculating the ejection fraction based upon the difference in volume or area at the two or more times in the cardiac cycle. The method can be used to determine a location for an intervention, such as placement of a pacemaker pacing lead, and may be performed before and after an intervention to assess the impact of the treatment on cardiac function.

An auscultation system includes a transducer for generating an acoustic signal at a transducing location of the subject, and a sensor for receiving an attenuated acoustic signal at a sensing location of the subject. The attenuated signal received at the sensing location is digitized, and may be analyzed in the frequency and / or time domain. The comparison of the digitized attenuated signal against the initial transduced signal allows for the computation of the degree of acoustic attenuation between the transducing and sensing locations. Acoustic attenuation may be utilized to generate an intensity ratio. The ejection fraction of the heart subject may then be computed by correlation to the intensity ratio. Pulse echo methods are also disclosed. The echo transducer is oriented on the subject and generates a series of signal pulses. The return echo on the pulse is then received and a brightness encoded image is produced. The return echo provides location data on the internal structures of the subject including location, motion and speed.

Methods to identify and risk stratify disease states, cardiac structural defects, functional cardiac deficiencies induced by teratogens and other toxic agents, pathological substrates, conduction delays and defects, and ejection fraction using single channel biological data obtained from the subject. A modified Matching Pursuit (MP) algorithm may be used to find a noiseless model of the data that is sparse and does not assume periodicity of the signal. After the model is derived, various metrics and subspaces are extracted to characterize the cardiac system. In another method, space-time domain is divided into a number of regions (which is largely determined by the signal length), the density of the signal is computed in each region and input to a learning algorithm to associate them to the desired cardiac dysfunction indicator target.

A method of real time ultrasound imaging of an object in at least three two-dimensional scan planes that are rotated around a common axis, is given, together with designs of ultrasound transducer arrays that allows for such imaging. The method is also introduced into a monitoring situation of cardiac function where, combined with other measurements as for example the LV pressure, physiological parameters like ejection fraction and muscular fiber stress is calculated.

Methods and apparatuses relate to an implantable device for providing contractile assistance to an organ. The device may include an actuator and anchors located on either side of the actuator. The anchors engage with oppositely positioned tissue walls of an organ chamber, and provide contractile assistance to the organ, repeatedly, at appropriate times. For example, the device may be implanted within the right ventricle, anchored to the right ventricular free wall and the ventricular septum. The device may function to bring the opposing walls of the ventricle toward one another, synchronized with the pacing of the heart, resulting in an improved ejection fraction of blood from the chamber. In some embodiments, the actuator includes a bladder that is configured to contract upon receiving an inflow of pressurized fluid therein. When the fluid exits therefrom, the bladder relaxes back to an initial, extended state.

A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).

The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

An ultrasonic imaging system and method are described for quantification and display of myocardial wall thickening. The endocardial and epicardial borders in an image sequence are defined over a heart cycle and changes in the distance between the borders are tracked at specified locations around the myocardium over the heart cycle, The changes in distance are presented to the user in a graphical format, preferably together with another measure of the cardiac cycle such as chamber volume variation, ejection fraction, or the ECG waveform. The changes in the distance of chord lengths across the myocardium provide a direct indication of wall thickness variation at the specified locations. Preferably the tracking of the specified locations over the heart cycle is done by speckle tracking. The inventive technique can also represent strain at the specified locations of the myocardium.

The invention provides serum miRNA relevant to a chronic heart failure and application of the serum miRNA. The invention provides application of peripheral blood miRNAs to the chronic heart failure as biomarker risk assessment / diagnosis and prognosis. Hsa-miR-4491, hsa-miR-1285-3p, hsa-miR-665, hsa-miR-660-3p, hsa-miR-206, hsa-miR-1268b, hsa-miR-130a-3p and hsa-miR-330-3p have differential expressions in peripheral blood of heart failure patients. It is proved that the peripheral blood hsa-miR-665 and the like can perform specific diagnosis on the chronic heart failure, the expression level of the hsa-miR-665 and the like is relevant to ejection fraction, and the hsa-miR-665 has an assessment and prognosis effect. Thus, by detecting the expression level of the miRNAs, the existing chronic heart failure can be predicted and coordinately diagnosed, or prognosis of the chronic heart failure can be estimated.

A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).

In a method and apparatus for measuring the ejection fraction in a mammalian heart, the opening and closing of a heart valve is sensed with an implanted sensor, and a pre-ejection period is measured as a function of the sensed opening and closing of the heart valve. The ventricular ejection time also is measured, and the ejection fraction is determined as a function of the measured pre-ejection period and the ejection time.

Embodiments of the invention provide a method, system and computer program product for artificially intelligent ejection fraction determination. In a method for artificially intelligent ejection fraction determination, a neural network is loaded into memory of a computer, that has been trained with different sets of cardiac imaging data acquired during imaging of a ventricle for different hearts and a known ejection fraction for each of the sets. Then, a contemporaneous set of imaging data is acquired of a ventricle of a heart and the contemporaneous set of imaging data is provided to the neural network. Finally, an ejection fraction determination output by the neural network is displayed in a display of the computer without tracing a ventricle boundary of the heart.

An Integrated CardioRespiratory (ICR) System is provided for continuous Ejection Fraction (EF) measurement using a wearable device comprising a plurality of acoustic sensors. The ICR system performs signal processing computations to characterize cardiac acoustic signals that are generated by cardiac hemodynamic flow, cardiac valve, and tissue motion, and may use advanced machine learning methods to provide accurate computation of EF.

The invention discloses a health management service system and method based on dynamic monitoring and analysis of heart functions. The system includes a heart health service cloud platform, a connected heart function intelligent monitoring and early warning device, an intelligent mobile terminal and a management subsystem connected with a medical service institution information platform. The mechanical vibration of the heart is monitored in vitro by a portable intelligent wearable device, vibration information of the heart is obtained in real time and non-invasively, and with combination of digital processing, machine learning and artificial intelligence technology pattern recognition and intelligent diagnosis, the abnormal physical structure and pulse rhythm of the heart are found in theearly stage, such as valvular lesions, abnormal movement of heart wall, change of the ejection fraction of the heart, arrhythmia and the like. With combination of an early warning reporting system, the purposes of early warning and timely medical care for heart disease can be realized. The system has great significance for early warning and monitoring and contrast postoperative rehabilitation monitoring of serious arrhythmia, angina pectoris and acute myocardial infarction, daily monitoring of home-based elderly people and physical exercise people.

A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of the heart, an increase in ejection fraction, an increase in glucose oxidation or a decrease in fatty acid oxidation, as determined by conventional methods known in the art.

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

A system uses integrated spatio-temporal analysis in X-ray angiography, for example, by using spatial information within each image frame and temporal information between image frames to provide robust and accurate estimation of stroke area and volume, two and three dimensional ejection fraction and to accommodate patient heart variation. A system determines patient heart related parameters for use in patient heart imaging examination. An image data processor processes data representing multiple cardiac images of a patient over multiple heart beat cycles of the patient to derive data representing a distribution curve of a heart section area over multiple heart beat cycle times and indicating heart section area change over a heart beat cycle. An area processor determines a heart section area in response to user command. Also a computation processor determines a heart function parameter in response to the determined heart section area and the indicated heart section area change.

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

The invention discloses a convolutional neural network information processing system and method based on cardiac function dynamic monitoring. The convolutional neural network information processing system comprises a 14-layer efficient convolutional neural network. The convolutional neural network information processing technology is applied to a portable heart intelligent patch system, and is worn on the chest wall of a human body in the form of wearable equipment For monitoring mechanical vibration of the heart in vitro and obtaining vibration information of the heart continuously in real time in a non-invasive mode, and by combining digital processing, machine learning and artificial intelligence technical mode recognition and intelligent diagnosis, the convolutional neural network information processing technology can find physical structure and pulsation rhythm abnormalities such as valvular lesion, abnormal movement of the heart wall, heart ejection fraction change and arrhythmiaof the heart in the early stage. And by combining an early warning report system, the convolutional neural network information processing technology can achieve the purposes of early warning of heartdiseases and timely medical care. The convolutional neural network information processing technology is of great significance to early warning and monitoring of severe arrhythmia, angina pectoris andacute myocardial infarction, rehabilitation monitoring after a contrast operation, daily monitoring of home-based care people and sports people.

In an ischemia detection method, and in an ischemia detector and a cardiac stimulator embodying an ischemia detector, a workload of a patient is measured, as is an ejection fraction (EF) associated with the heart of the patient is determined. A predetermined reference relation between EF and workload for the patient is stored, and an analysis unit detects a state of ischemia of the patient from deviation in the determined EF for various workloads from the stored reference relation.

The invention relates to the field of medicines, and specifically relates to a medicine composition and an application thereof. The medicine composition is mainly composed of a first component and a second component, wherein the first component is total saponins of astragalus, and the second component is angelica sinensis volatile oil; or the first component is astragaloside, and the second component is ferulic acid. The medicine composition is applied to preparing medicines for preventing and / or treating atherosclerosis. The medicine composition has significant effect on reducing serum cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterin and serum triglyceride, and improving a cardiac function ejection fraction, so that the medicine composition has the efficacy of preventing or treating hyperlipemia. Therefore, atherosclerosis and cardiovascular and cerebrovascular diseases are prevented and treated.

The continuous and dynamic computation of ejection fraction (EF) includes training a neural network with different sets of cardiac imaging data acquired of a ventricle for different hearts and a known EF for each of the sets and then loading the trained neural network into memory of a computer. Afterwards, contemporaneous sets of imaging data of a ventricle of a heart are continuously acquired according to a specified view. For each corresponding set of imaging data, an image quality value may then be computed, and the corresponding set of imaging data may be provided to the neural network. The neural network, in response, provides, as output, an EF determination output without tracing a ventricle boundary of the heart. Thereafter, both the computed image quality value and the EF determination output may be displayed in a display of the computer.

The invention relates to a natural medicine composition used for treating cardiovascular diseases. The natural medicine composition comprises aconitine, liquiritin and 6-gingerol and is prepared into oral preparations, such as hard capsules, soft capsules, tablets, granules, powder, pills, tea bags and medicinal liquor by utilizing synergistic effects of the components. The composition can achieve the effects of treating rats with heart failures caused by myocardial infarction, increasing the ejection fractions and fractional shortening of the rats, obviously improving cardiomyocyte morphologies, reducing the degree of cardiac collagen fibrosis and reducing the contents of aldosterone and atrial natriuretic peptide in serums, and has the function of treating cardiovascular diseases. The composition has definite pharmacodynamic effects, is rigorous in quality control and small in taking dosage and is convenient to take.

The invention provides a GLP-1 small molecule compound with cardiovascular benefits, which not only can be used for treatment of diabetes mellitus, but also can be independently or jointly applied as a cardiovascular protective agent and has the pharmaceutical application of reducing cardiovascular adverse events or reducing cardiovascular adverse events in type 2 diabetes mellitus. The reduction of cardiovascular adverse events comprises reduction of the incidence rate of myocardial infarction of patients, reduction of the hospitalization frequency caused by heart failure, reduction of the risk of myocardial infarction and stroke of patients, and reduction of the cardiovascular death risk of heart failure of adults with reduced ejection fraction and the hospitalization risk caused by heart failure (NYHA II-IV level).

The invention discloses an application of an ester group-containing aromatic propionamide compound and metabolites thereof in preparation of a drug for treating heart failure. The ester group-containing aromatic propionamide compound is C25H17F3N4O4. The invention has the outstanding effects that the ester group-containing aromatic propionamide compound can improve the ejection fraction, the shortaxis shortening rate and the cardiac output reduction of rats with chronic heart failure, and improve the LVSP of the rats with heart failure. The compound has a positive effect in the application ofpreparing the medicine for treating heart failure.